---
title: "J&J Says TECVAYLI+TALVEY Cuts Risk Of Disease Progression Or Death By 89% In Multiple Myeloma Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293623520.md"
description: "Johnson & Johnson reported positive Phase 3 MonumenTAL-6 trial results, showing Tecvayli+Talvey and Talvey+pomalidomide regimens significantly improved progression-free survival in relapsed/refractory multiple myeloma patients. The Tec-Tal regimen reduced disease progression or death risk by 89% versus standard of care. This marks the first Phase 3 trial evaluating a dual-antigen BCMA/GPRC5D targeting regimen in this patient population."
datetime: "2026-07-23T13:09:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293623520.md)
  - [en](https://longbridge.com/en/news/293623520.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293623520.md)
generator: "portal-rs"
---

# J&J Says TECVAYLI+TALVEY Cuts Risk Of Disease Progression Or Death By 89% In Multiple Myeloma Trial

Add  as your preferred news source on Google

 Add Now

Johnson & Johnson (JNJ) on Thursday reported positive topline results from the Phase 3 MonumenTAL-6 study, showing that two Tecvayli- and Talvey-based regimens significantly improved progression-free survival in adults with relapsed or refractory multiple myeloma compared with standard of care.

The study evaluated Tecvayli plus Talvey (Tec-Tal) and Talvey plus pomalidomide (Tal-P) against the investigator's choice of elotuzumab, pomalidomide and dexamethasone (EPd) or pomalidomide, bortezomib and dexamethasone (PVd) in patients who had received one to four prior lines of therapy, including an anti-CD38 antibody and lenalidomide.

Both experimental regimens met the study's primary endpoint of progression-free survival. The Tec-Tal regimen reduced the risk of disease progression or death by 89% and the risk of death by 62% versus standard of care. The Tal-P regimen reduced the risk of disease progression or death by 73%.

Johnson & Johnson said MonumenTAL-6 is the first Phase 3 trial to evaluate a dual-antigen regimen targeting both BCMA and GPRC5D in relapsed or refractory multiple myeloma.

"These findings add to a growing body of Phase 3 evidence evaluating the survival outcomes associated with the early use of immunotherapy doublets in the treatment journey," said Ajay K. Nooka, Director, Myeloma Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.

Johnson & Johnson shares closed at $255.63 on Wednesday, up 2%. 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [BMS bags first FDA approval for CELMoD franchise with Zenbexus](https://longbridge.com/en/news/295947034.md)
- [J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B](https://longbridge.com/en/news/294502666.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing](https://longbridge.com/en/news/296318843.md)
- [CMI adopts orphan drug field with dedicated center of excellence](https://longbridge.com/en/news/296242891.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**